|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1399 NEW YORK AVENUE NW |
Address2 | SUITE 300 |
| City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 15920-12
|
||||||||
|
6. House ID# 314640000
|
||||||||
| TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Shannon Steward |
Date | 1/20/2013 8:33:43 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues related to the PPPS rule involving stroke guidelines. Proposals to reduce Medicare payment for Part B biologics. Concerns regarding Medicare payment policies for Biologics; issues relating to Prescription Drug User Fee Act and SP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 942- American Research & Competitiveness Act of 2011.; Medicare coverage and payment of Part B drugs and biologics; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eldgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; proposed cuts to Part B reimbursement; implementation of Health reform; Legislation for CMS.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
Vice President of Government Affairs |
|
Darin |
Gardner |
|
Sr. Director Government Affairs |
|
Katherine |
Martin |
|
Director of Government Affairs |
|
David |
Burt |
|
Director of Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of HR 1; Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus, issues relating to PDUFA, stimulus, issues relating to comparative effectiveness and CMS coverage of FDA approved therapies; issues related to the PPS rule involving stroke guidelines; Implementation of the the follow-on biologics in P.L. 1111-148 "Patient Protection and Affordable Care Act; FY13 Labor HHS Appropriations legislation; issues related to FDA user fee reauthorization; H.R. 942 S. 1577, S 3187; Pedigree and biologics issues; H.R. 905; ASP issues: H.R.5651; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; Medicare prescription Drug and Modernization Act of 2003; Avastin use in breast cancer treatment; general patient reform issues; implementation of the Affordable Care of 2010; proposed cuts to Part B reimbursement; 340 B reimbursement policy; Medicare/Medicaid Reimbursement
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darin |
Gardner |
|
Sr. Director Government Affairs |
|
David |
Burt |
|
Director |
|
Katherine |
Martin |
|
Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Intellectual Property and Process Patent Issues - HR 1908. Patent Reform Act (all provisions); Cyber security , implementation of S.23: American Invents Act, Implementation of HR 1249; Transpacific partnership
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darin |
Gardner |
|
Sr. Director Government Affairs |
|
Evan |
Morris |
|
Vice President of Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
FY14 appropriations bills, including issues related to FDA funding and drug approval/review oversight process; issues related to comprehensive tax U.S. corporations, and tax extenders, including R&D tax credit. S.3521, Family and Business Tax Cut Certanity Act of 2012 (tax "extenders"). Corporate tax reform issues. Fiscal cliff legislation. American Taxpayer relief act (HR 8); R&D Tax Credit issues; S. 3521, S.1577, Greater Research Opportunities with Tax Help Act: H.R. 942, American Research and Competitiveness Act of 2011; HR. 8; Research and Development Tax credit, year-end tax issues: Monitoring proposals on US tax treatment of foreign-owned US corporations;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eli |
Kogan |
|
Asst. Director |
|
Darin |
Gardner |
|
Sr. Director Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY13 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HI/AID programs, hepatitis screening, care and treatment and access to breast cancer treatment; issues related to FDA &HHA program funding, FY13 Labor Health and Human Services and Education and related agencies appropriations bill.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eli |
Kogan |
|
Asst. Director |
|
Evan |
Morris |
|
Vice President of Government Affairs |
|
Darin |
Gardner |
|
Sr. Director Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Monitor DrugSafety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |